Solux Co. Ltd (290690) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Solux Co. Ltd stock KRW 1,146, price KRW 3,805, that is 69.9% below the price, quality 24 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 1,898 KRW – 34,400 KRW · fair‑value band 855.22 KRW – 1,710 KRW · the 3,805 KRW price screens above the 1,146 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Solux Co. in your weekly email
Every Wednesday you see whether Solux Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Solux Co., Ltd. manufactures and supplies indoor, outdoor, and special purpose lighting products in South Korea and internationally. The company was founded in 1995 and is headquartered in Gongju-si, South Korea.
Stock analysis
Solux Co. Ltd (290690) currently trades at 3,805 KRW, while our model-based Fair Value estimate is 1,146 KRW, 70% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.
Scenario range: 855.22 KRW (bear) to 1,710 KRW (bull), the price of 3,805 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Solux Co. Ltd reported revenue of 38.3B KRW in FY2025 versus 70.0B KRW in FY2021, a compound −14.0%/yr. Reported net income was −7.7B KRW in FY2025.
Key figures
Market cap 185B KRW (≈ $137M) Micro · P/E ratio 15.0 · P/S ratio 4.48 · EPS (TTM) 255.17 KRW · Net margin 32.4% · Return on equity 14.6% · Return on assets (EBIT) −1.9% (5-year average) · Operating margin −25.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 37% below its 52-week high and 45% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −70%, 290690 screens richer than that median.
Fair Value models
Bear855.22 KRWFair Value 1,146 KRWBull1,710 KRW
Price 3,805 KRW · Downside -69.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (218.82 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−24.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.9%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
8.8% (2020) → −17.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score24 · Bottom 25%
Fair Value upside−69.9% · Below median
Profitability
Return on equity (12 months)14.6% · Top 25%
Return on assets−5.5% · Above median
Net margin (12 months)32.4% · Top 25%
Operating margin (12 months)−25.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)9.1% · Above median
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)15.0× · Cheaper than median
P/B2.04× · Pricier than median
P/S (12 months)4.48× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)46· sector 0
PAST (return on equity)58· sector 0
HEALTH (low debt)93· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Solux Co. Ltd (290690) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 1,146 KRW versus a price of 3,805 KRW, about 70% lower (overvalued).
What is the fair value of 290690?
Our model-based fair value for Solux Co. Ltd is 1,146 KRW (as of Nov 4, 2026), built from audited fundamentals. The current price: 3,805 KRW.
What is the quality score of 290690?
Solux Co. Ltd has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Solux Co. Ltd (290690)?
Our model-based price target is the fair value of 1,146 KRW (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 855.22 KRW, optimistic scenario 1,710 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Solux Co. Ltd stock forecast for 2026?
Our models put fair value at 1,146 KRW, about 70% lower versus a price of 3,805 KRW (overvalued). Cautious scenario 855.22 KRW, optimistic scenario 1,710 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Solux Co. Ltd (290690)?
Solux Co. Ltd reported trailing-twelve-month revenue of about 41.4B KRW (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Solux Co. Ltd (290690)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Solux Co. Ltd it is 1,146 KRW per share (as of Nov 4, 2026), against a price of 3,805 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Solux Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 290690 trades above its calculated fair value: price 3,805 KRW, fair value 1,146 KRW, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 290690?
No. The price is what the market pays today (3,805 KRW); the fair value is what the company's own numbers justify (1,146 KRW). For Solux Co. Ltd the two are 2,659 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Solux Co. Ltd worth?
The market values Solux Co. Ltd at about 185B KRW (market capitalisation, as of Nov 4, 2026). Per share that is 3,805 KRW; our models calculate a fair value of 1,146 KRW per share.
What do the bullish and bearish scenarios say about 290690?
Our models span a range for Solux Co. Ltd: cautious scenario 855.22 KRW, base 1,146 KRW, optimistic 1,710 KRW per share (as of Nov 4, 2026, price 3,805 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 290690?
Solux Co. Ltd trades at a price-to-earnings ratio of 15.0 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1,146 KRW is built from several models across several years. Other multiples: P/B 2.0, P/S 4.5.
How solid is the balance sheet of Solux Co. Ltd (290690)?
Balance-sheet figures for Solux Co. Ltd (as of Nov 4, 2026): return on equity 14.6%, debt of 0.14 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is 290690 from its 52-week high?
Solux Co. Ltd trades at 3,805 KRW, about 37% below its 52-week high of 6,020 KRW and 45% above the low of 2,620 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,146 KRW is for.
Which stocks are comparable to Solux Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Solux Co. Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price 3,805 KRW, calculated fair value 1,146 KRW (−70%), Quality Score 24/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 290690 calculated?
We run Solux Co. Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 1,146 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Solux Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Solux Co. Ltd (290690)?
The closing price on Nov 6, 2026 was 3,805 KRW. Our model-based fair value is 1,146 KRW, about 70% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Solux Co. Ltd right now?
The price sits above even our optimistic bull case (1,710 KRW). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (855.22 KRW to 1,710 KRW) leaves room in how you read the outcome.
Key figures of Solux Co. Ltd
How large is the market capitalisation of Solux Co. Ltd (290690)?
The market capitalisation of Solux Co. Ltd is 185B KRW (≈ $137M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Solux Co. Ltd (290690)?
The price-to-sales ratio of Solux Co. Ltd is 4.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Solux Co. Ltd (290690)?
Earnings per share at Solux Co. Ltd are 255.17 KRW (price ÷ EPS = P/E 15.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Solux Co. Ltd (290690)?
The net margin of Solux Co. Ltd is 32.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Solux Co. Ltd (290690)?
The return on equity (ROE) of Solux Co. Ltd is 14.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Solux Co. Ltd (290690)?
On an EBIT basis the return on assets of Solux Co. Ltd is −1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Solux Co. Ltd (290690)?
The operating margin of Solux Co. Ltd is −25.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Solux Co. Ltd (290690)?
Revenue at Solux Co. Ltd is growing +9.1% versus a year earlier (3y avg −11.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Solux Co. Ltd (290690) generate?
The free cash flow of Solux Co. Ltd is −3.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Solux Co. Ltd (290690) carry?
The net debt of Solux Co. Ltd is 35.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Solux Co. Ltd in the live analysis
One click puts Solux Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026